| Business Summary | | Cambridge
Antibody
Technology
Group
plc
(CAT)
is
a
biotechnology
company
based
in
the
United
Kingdom
with
an
advanced
platform
technology
for
the
rapid
isolation
of
human
monoclonal
antibodies,
which
have
potential
to
identify
and
treat
human
diseases.
CAT
uses
its
proprietary
technology
for
drug
discovery
and
drug
development,
exploiting
the
characteristics
of
antibodies
both
to
discover
and
validate
new
disease
targets
and
to
engineer
human
monoclonal
antibodies
as
treatments
for
human
diseases.
CAT's
platform
technology
mimics
aspects
of
the
human
immune
system
and
CAT
has
created
a
library
of
over
100
billion
distinct
human
monoclonal
antibodies.
CAT
is
exploiting
the
value
of
its
technology
to
help
discover
and
validate
the
role
of
specific
targets
in
disease
both
through
internal
programs
and
by
working
with
collaborative
partners. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Cambridge
Antibody
Technology
Group
is
a
UK
biotechnology
company
using
proprietary
technologies
in
human
monoclonal
antibodies
for
drug
discovery
and
drug
development.
For
the
six
months
ended
3/31/01,
revenue
rose
4%
to
L6.6
million.
Net
loss
according
to
U.S.
GAAP
decreased
12%
to
L10.7
million.
Revenues
reflect
increased
license
fees
due
to
amounts
paid
by
Immunex.
Loss
also
benefited
from
higher
interest
income
due
to
higher
average
investment
balances. | More
from
Market Guide: Significant
Developments |
| Officers | |
| Position | Peter Garland, Ph.D., 67 | Chairman | David Chiswell, Ph.D., 47 | CEO,
Director | Jason Avery, 39 | Sr.
VP - Bus. Alliances | Nigel Burns, Ph.D., 40 | Sr.
VP - Preclinical Devel. | Alexander Duncan, Ph.D., 39 | VP
- Drug Discovery |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|